Ipsen Bundle
Who Really Owns Ipsen?
Understanding the ownership structure of a company is crucial for investors and analysts alike. It reveals the power dynamics, strategic direction, and potential risks. Uncover the intricate web of Ipsen SWOT Analysis, a leading biopharmaceutical company, and its journey from a family-founded enterprise to a global player.
This exploration into Ipsen's ownership will provide critical insights for anyone interested in Ipsen pharmaceuticals, from individual investors to seasoned financial professionals. We'll examine the Ipsen shareholders, the Ipsen company ownership structure, and the Ipsen history to understand the company's evolution. Discover who are the major shareholders of Ipsen and how the ownership influences the company's future, including its financial performance and market capitalization.
Who Founded Ipsen?
The story of the Ipsen company begins in 1929, when Dr. Henri Beaufour established Beaufour Laboratories in Dreux, France. Initially, the company's focus was on digestive and neurological conditions, with its first product, Romarene, a rosemary-based medicine, addressing digestive ailments. This marked the inception of what would become a significant player in the pharmaceutical industry.
The early ownership of the company was firmly rooted in the Beaufour family. Henri Beaufour's sons, Albert and Gérard Beaufour, joined the company, contributing to its growth throughout the 1950s and 1960s. This family-centric approach shaped the company's culture and strategic direction in its formative years.
Following Albert Beaufour's passing in 2000, his children, Anne Beaufour and Henri Beaufour, took over the leadership, ensuring the family's continued stewardship into the new millennium. The family's influence remained strong for decades before the company's initial public offering (IPO) in 2005.
Founding and Early Focus
Dr. Henri Beaufour founded Beaufour Laboratories in 1929 in Dreux, France. The initial focus was on digestive disorders and neurological conditions. The first product was Romarene, a rosemary-based medicine.
Family Involvement
Henri Beaufour's sons, Albert and Gérard Beaufour, joined the company. They played a key role in the company's expansion during the 1950s and 1960s.
Continued Family Leadership
After Albert Beaufour's death in 2000, Anne Beaufour and Henri Beaufour took over leadership. This ensured the family's continued involvement into the new millennium.
IPO and Family Ownership
In 2005, when Ipsen went public, the Beaufour family still held a significant stake. The IPO marked a transition while maintaining strong family influence.
Early Ownership Structure
The company remained family-owned for over 90 years. The exact initial shareholding percentages aren't publicly detailed. The family maintained control for many decades.
IPO Impact
The IPO in 2005 marked a significant change in the ownership structure. It allowed for broader market participation while the family maintained a substantial share.
Key Takeaways
The early years of Ipsen, or the Ipsen company, were characterized by strong family control. This shaped its strategic decisions and culture. The Ipsen ownership remained primarily within the Beaufour family for many decades. This changed with the IPO, but the family retained a significant stake. The company's history reflects a transition from a family-owned business to a publicly traded entity.
- The Beaufour family founded the company in 1929.
- The family maintained significant control for over 90 years.
- The IPO in 2005 marked a major shift in ownership.
- The family remained major Ipsen shareholders after the IPO.
Ipsen SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Ipsen’s Ownership Changed Over Time?
The ownership of the Ipsen company has seen a significant shift over time. Initially a privately held family business, it transitioned to a publicly traded entity. A pivotal moment was the Initial Public Offering (IPO) on Euronext Paris in 2005. This IPO, priced at €22.20 per share, valued the company at €1.84 billion and generated €324 million.
Despite the IPO, the Beaufour family maintained a strong presence, holding a significant stake. This transition marked a change in the Ipsen ownership structure, opening it up to a broader investor base while still retaining family influence. The evolution of the company from a private to a public entity has shaped its trajectory and its relationship with stakeholders.
| Event | Date | Impact on Ownership |
|---|---|---|
| IPO on Euronext Paris | 2005 | Made Ipsen a publicly traded company, increased investor base. |
| Beaufour Family Stake | 2005 (Post-IPO) | Retained a 76% stake, maintaining significant control. |
| Current Ownership (2024-2025) | Ongoing | Beaufour family holds 57% of shares and controls 73% of voting rights. |
As of the latest data available in 2024-2025, the Beaufour family remains the largest shareholder group of Ipsen. Henri Beaufour and Anne Beaufour each hold 26.03% of the equities. The Schwabe Family also holds a notable stake of 4.577%. Ipsen, trading under the ticker symbol IPN on Euronext Paris, is part of the SBF 120 index. The company's market capitalization is approximately $9.9 billion as of June 13, 2025, with 83 million shares outstanding. The company's solid financial results and a robust balance sheet position Ipsen for continued growth, attracting further investor interest. For more detailed insights into the company's strategic direction, you can read about the Growth Strategy of Ipsen.
Key Takeaways on Ipsen Ownership
The Beaufour family has maintained a significant influence on Ipsen, even after the IPO.
- Ipsen is a publicly traded company listed on Euronext Paris.
- The Beaufour family owns a majority stake, ensuring their continued influence.
- Ipsen's market capitalization is approximately $9.9 billion as of June 13, 2025.
- The company's 2024 sales reached €3,400.6 million.
Ipsen PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Ipsen’s Board?
The Board of Directors at Ipsen S.A. plays a crucial role in shaping the company's direction and overseeing its operations. As of May 21, 2025, the board includes a mix of members, including representatives of major shareholders, independent directors, and employee representatives. Marc de Garidel has served as the Chairperson of the Board since July 2016, with Antoine Flochel as Vice Chairman. Key figures representing major shareholders include Anne Beaufour and Henri Beaufour, members of the founding Beaufour family, which holds a significant stake in the company. Other directors include Naomi Binoche and Laetitia Ducroquet, who are employee representatives. The board also includes independent directors such as Margaret Liu, Pascal Touchon, Piet Wigerinck, Karen Witts, and Carol Xueref. David Loew, the Chief Executive Officer since July 1, 2020, also serves on the board.
At the Annual General Meeting on May 21, 2025, the terms of office for David Loew, Antoine Flochel, Margaret Liu, and Karen Witts were renewed for four years. This reflects a commitment to continuity and experience within the leadership structure. The board's composition ensures a balance of shareholder interests, independent oversight, and employee representation, contributing to sound governance practices. The Marketing Strategy of Ipsen is influenced by the decisions and oversight of this board, which is responsible for the company's strategic direction.
| Board Member | Role | Affiliation |
|---|---|---|
| Marc de Garidel | Chairperson | |
| Antoine Flochel | Vice Chairman | |
| Anne Beaufour | Director | Highrock S.àr.l. |
| Henri Beaufour | Director | Beaufour Family |
| David Loew | Director, CEO |
The Beaufour family's significant ownership, holding 57% of the shares and controlling 73% of the voting rights, gives them substantial influence over the company's strategic decisions. This structure, similar to a dual-class arrangement, allows the family to maintain considerable control. The company's Articles of Association were updated on June 13, 2024, to incorporate changes related to written board consultations and remote meetings, reflecting modern governance practices. At the Annual General Meeting on May 21, 2025, all 30 resolutions proposed by the Board of Directors were approved, including the distribution of a dividend of €1.40 per share for the 2024 financial year.
Key Takeaways on Ipsen Ownership
The Board of Directors at Ipsen is a mix of shareholder representatives, independent directors, and employee representatives.
- The Beaufour family holds a significant stake, influencing key decisions.
- The board renewed the terms of several directors at the May 2025 AGM.
- The company's governance reflects modern practices.
- A dividend of €1.40 per share was approved for 2024.
Ipsen Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Ipsen’s Ownership Landscape?
Over the past few years, the ownership profile of the Ipsen company has shown dynamism, particularly in its strategic moves to strengthen its position in specialty care. In 2024, Ipsen demonstrated robust financial results, with total sales reaching €3,400.6 million, reflecting a 9.9% increase at constant exchange rates compared to 2023. Core operating income grew by 10.8% to €1,109.4 million, with a core operating margin of 32.6% of total sales. This performance was driven by growth across all therapeutic areas, notably a 67.4% increase in the Rare Diseases portfolio. The company is actively replenishing its pipeline and anticipating sustained growth.
Regarding strategic transactions, Ipsen pharmaceuticals has been active in business development. In July 2024, Ipsen Pharma SAS entered an exclusive license agreement with Day One Biopharmaceuticals, Inc. to commercialize tovorafenib outside the United States, involving an upfront license fee of approximately $71 million. Earlier in March 2024, Ipsen Pharma SAS also entered an exclusive license agreement with Sutro Biopharma, Inc. for STRO-003, with an upfront license fee of $50 million. These deals highlight Ipsen's strategy of fueling its pipeline through external innovation. For more details on Ipsen's history and future plans, see the Growth Strategy of Ipsen.
| Metric | 2024 | 2023 |
|---|---|---|
| Total Sales (€ million) | €3,400.6 | €3,100.0 |
| Core Operating Income (€ million) | €1,109.4 | €1,001.0 |
| Core Operating Margin | 32.6% | 32.3% |
| Rare Diseases Portfolio Growth | 67.4% | N/A |
The Beaufour family continues to maintain significant control of Ipsen ownership, holding 57% of shares and 73% of voting rights as of 2024. There's a clear trend towards increased institutional ownership and strategic partnerships within the biopharmaceutical industry. Ipsen anticipates total sales growth greater than 5.0% at constant exchange rates for 2025, with a core operating margin exceeding 30.0%. Ipsen's strong financial health, with a robust balance sheet and cash generation, supports its ambitions for continued growth.
Who Owns Ipsen?
The Beaufour family controls a significant portion, with 57% of shares and 73% of voting rights as of 2024.
Recent Financial Performance
In 2024, Ipsen's sales reached €3,400.6 million, a 9.9% increase. Core operating income was €1,109.4 million.
Strategic Partnerships
Ipsen has entered into license agreements with Day One Biopharmaceuticals and Sutro Biopharma to bolster its pipeline.
Future Outlook
The company anticipates total sales growth exceeding 5.0% at constant exchange rates for 2025.
Ipsen Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Ipsen Company?
- What is Competitive Landscape of Ipsen Company?
- What is Growth Strategy and Future Prospects of Ipsen Company?
- How Does Ipsen Company Work?
- What is Sales and Marketing Strategy of Ipsen Company?
- What is Brief History of Ipsen Company?
- What is Customer Demographics and Target Market of Ipsen Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.